echemi logo
web-logo
slogan
homepage
Product
  • Product
  • Supplier
  • Inquiry

    My ECHEMI

    EN

    Home > Medical News > Medical Research Articles > InnoCare Announces the Acceptance of the Marketing Application of Tafasitamab in Combination with Lenalidomide in the Treatment of Relapsed/Refractory DLBCL in Hong Kong

    InnoCare Announces the Acceptance of the Marketing Application of Tafasitamab in Combination with Lenalidomide in the Treatment of Relapsed/Refractory DLBCL in Hong Kong

    • Last Update: 2022-09-07
    • Source: Internet
    • Author: User
    Tags

    peer review important

    pca facial products
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com